APTAHEM AB
0.27
SEK
0.00
(0.00%)
ISIN
SE0022447173
Return %
Stock
S&P 500
1Y
-77.39
14.20
3Y
-98.30
81.12
5Y
-99.50
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Knut Mikael Ingolf Lindstam
- Full Time Employees
- 6
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Medeon Science Park Malmö SN Sweden 205 12
- IPO Date
- Apr 17, 2017
- Website
- aptahem.com
- Similar Companies
- Business
- Aptahem AB (publ) Aptahem AB (publ) is a clinical-stage biotechnology company that develops RNA-based pharmaceuticals, known as aptamers, for the treatment of acute, life-threatening conditions involving coagulation, inflammation, and tissue damage; its lead candidate, Apta-1, targets sepsis and other severe inflammatory conditions such as septic shock, demonstrating anti-thrombotic, immunomodulating, and tissue-repairing properties in preclinical and early clinical studies. The company focuses on building a platform portfolio of multi-mechanistic aptamer-based therapies to address global unmet medical needs in critical care, with Apta-1 currently advancing toward Phase 2 evaluation in patients with acute inflammatory diseases. Founded in 2014 and headquartered at Norra Vallgatan 58 in Malmö, Sweden, Aptahem operates primarily in the healthcare sector, collaborating with academic institutions including Örebro University, Seattle Children’s Research Institute, and University Health Network in Canada. Aptahem advances its pipeline through strategic partnerships and business development, including a recent collaboration with Hongene Biotech to reduce manufacturing costs and enhance sustainability for Apta-1 production, as well as a strategic agreement with e-Projection Corp. in Japan to accelerate partnering opportunities. In September 2025, following a rights issue, the company prioritized a U.S. listing strategy to fund Phase 2 studies, expand its portfolio, and engage potential partners, while receiving strong interest from a European pharmaceutical company for collaboration. Recent milestones encompass completion of a Phase 1 first-in-human study in 2023 confirming Apta-1's safety and tolerability, GMP-certified production, multiple patent approvals across regions like Europe, the U.S., Japan, and Israel, and publications in journals such as British Journal of Pharmacology and Cells validating Apta-1's efficacy in sepsis models and coronaviral lung injury.